Treats symptomatic benign prostatic hyperplasia (BPH). ANDA 213300, held by Aurobindo Pharma. Dutasteride; Tamsulosin Hydrochloride.
As of Nov 16, 2026, ANDA 213300 (Dutasteride And Tamsulosin Hydrochloride), held by Aurobindo Pharma, was first approved by FDA on Jul 18, 2024, with 0 approved supplements and 0 published complete response letters.
Dutasteride and tamsulosin hydrochloride capsules are a combination of dutasteride, a 5-alpha-reductase inhibitor, and tamsulosin, an alpha-adrenergic antagonist, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. Limitations of Use: Dutasteride-containing products, including dutasteride and tamsulosin hydrochloride capsules, are not approved for the prevention of prostate cancer. 1.1 Benign Prostatic Hyperplasia (BPH) Treatment Dutasteride and tamsulosin hydrochloride capsules are indicated for the treatment of symptomatic BPH in men with an enlarged prostate. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 18, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dutasteride And Tamsulosin Hydrochloride0.5MG;0.4MG · capsule;oral | Dutasteride; Tamsulosin Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters